IMNN · Imunon, Inc. · Documents
$0.83
-0.05 (-5.26%)
At close · Oct 28
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$4.92M
Shares
5.61M
Volume · Oct 28
194.93K
Avg daily vol (3M)
113.97K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| S-1/A | Imunon appointed Maxim Group LLC as exclusive placement agent on a reasonable best efforts basis. Compensation includes 7.0% of gross proceeds, legal-expense reimbursement up to $125,000 less the Advance, and placement warrants equal to 5.0% of the base offering sold. | 2026-10-28 | — | |
| S-1 | Imunon, Inc. proposes a best-efforts offering of up to 20,000,000 common shares at an assumed $1.25 per share, accompanied by warrants for up to 70,000,000 shares; 91,000,000 shares total may be issuable upon warrant exercises. | 2026-10-27 | — | |
| 8-K | Imunon, Inc. made its October 2026 investor presentation available on October 26, 2026 and expects to use it in investor calls and/or conferences. | 2026-10-27 | 2026-10-26 | |
| 8-K | Imunon agreed to sell ThermoDox assets to VoxelDox Therapeutics, Inc.; closing requires at least $2.5 million in financing, with Imunon to receive 4.76% of VoxelDox, up to $16.5 million in milestones and 3.5% to 6% royalties on net sales. | 2026-10-21 | 2026-10-20 | |
| 8-K | On September 28, 2026, Imunon, Inc. exchanged $1,200,000 of Secured Promissory Note A-1 principal and accrued interest with Streeterville Capital, LLC for 120 Series B Preferred Stock shares carrying a $12,000 stated value and 8% per year preferred return. | 2026-09-29 | 2026-09-28 | |
| 10-Q | — | 2026-08-11 | 2026-06-30 | |
| 8-K | — | 2026-08-11 | — | |
| 8-K | — | 2026-08-11 | — | |
| 8-K | — | 2026-06-30 | 2026-06-29 | |
| 8-K | — | 2026-06-16 | — | |
| 8-K | — | 2026-06-04 | 2026-06-01 | |
| 8-K | — | 2026-05-12 | — | |
| 10-Q | — | 2026-05-12 | 2026-03-31 | |
| 8-K | — | 2026-05-04 | 2026-05-01 | |
| DEF 14A | — | 2026-05-04 | — | |
| ARS | — | 2026-05-04 | 2025-12-31 | |
| 8-K | — | 2026-03-31 | — | |
| 10-K | — | 2026-03-31 | 2025-12-31 | |
| 8-K | — | 2026-03-23 | — | |
| 8-K | — | 2026-02-05 | 2026-02-02 | |
| 8-K | — | 2026-01-07 | — | |
| 8-K | — | 2025-12-31 | 2025-12-29 | |
| 10-Q | — | 2025-11-13 | 2025-09-30 | |
| 8-K | — | 2025-11-13 | — | |
| 8-K | — | 2025-08-28 | 2025-08-27 | |
| 10-Q | — | 2025-08-05 | 2025-06-30 | |
| 8-K | — | 2025-08-05 | — | |
| 8-K | — | 2025-07-28 | — | |
| 8-K | — | 2025-07-23 | 2025-07-21 | |
| 8-K | — | 2025-07-22 | — | |
| 8-K | — | 2025-07-14 | 2025-07-11 | |
| 8-K | — | 2025-07-11 | — | |
| 8-K | — | 2025-06-13 | — | |
| ARS | — | 2025-06-11 | 2024-12-31 | |
| 8-K | — | 2025-06-09 | — | |
| DEF 14A | — | 2025-06-09 | — | |
| PRE 14A | — | 2025-05-30 | — | |
| 8-K | — | 2025-05-30 | — | |
| S-1 | — | 2025-05-30 | — | |
| 8-K | — | 2025-05-27 | 2025-05-23 | |
| 8-K | — | 2025-05-22 | — | |
| 8-K | — | 2025-05-20 | 2025-05-19 | |
| S-1/A | — | 2025-05-19 | — | |
| 8-K | — | 2025-05-13 | 2025-05-12 | |
| S-1/A | — | 2025-05-13 | — | |
| 10-Q | — | 2025-05-12 | 2025-03-31 | |
| 8-K | — | 2025-05-12 | — | |
| S-1 | — | 2025-04-04 | — | |
| 8-K | — | 2025-03-24 | — | |
| 10-K | — | 2025-02-27 | 2024-12-31 |
Showing 1–50 of 175 filings